AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 26 - (NewsRx Network) -- by Sonia Nichols, senior medical writer - A multinational research team has reported carboxymethyl dextran benzylamide (CMBD7), which inhibits breast cancer neovascular growth and cancer spread in mice, increases the effectiveness of tamoxifen, a breast cancer drug.
Researchers in France and the U.S. have produced a study showing CMBD7 enhances the effectiveness of tamoxifen (TAM) when administered to mice implanted with breast cancer cells by inhibiting a process known as angiogenesis. Although the compound is currently being studied in animals, further analysis may demonstrate the potential effectiveness of CMBD7 in patients with breast cancer.
The study was a joint effort by researchers at the University of Paris and the M.D. Anderson Cancer Center in Houston, Texas. Scientists at these institutions implanted breast cancer cells expressing specific cancer genes into several mice with deficient immune systems. They then administered CMDB7 and TAM to the mice for several weeks thereafter.
"For seven weeks, the CMBD7 (300 mg/kg/week) and TAM-(20 mg/kg/week)-treated groups showed tumor growth inhibition of about 66% and 76%, respectively," said Rozita Bagheri-Yarmand and coworkers, Universite' Paris.
"Combined treatments with CMDB7 and TAM block the tumor development by 94% and induce a complete regression in 4 of 8 mice," they added.
When ...